| Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008 ZM Younossi, M Stepanova, M Afendy, Y Fang, Y Younossi, H Mir, ... Clinical gastroenterology and hepatology 9 (6), 524-530. e1, 2011 | 1444 | 2011 |
| The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe ZM Younossi, D Blissett, R Blissett, L Henry, M Stepanova, Y Younossi, ... Hepatology 64 (5), 1577-1586, 2016 | 1299 | 2016 |
| Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver‐related mortality ZM Younossi, M Stepanova, N Rafiq, H Makhlouf, Z Younoszai, ... Hepatology 53 (6), 1874-1882, 2011 | 739 | 2011 |
| Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates Z Younossi, M Stepanova, JP Ong, IM Jacobson, E Bugianesi, A Duseja, ... Clinical gastroenterology and hepatology 17 (4), 748-755. e3, 2019 | 696 | 2019 |
| Nonalcoholic fatty liver disease in lean individuals in the United States ZM Younossi, M Stepanova, F Negro, S Hallaji, Y Younossi, B Lam, ... Medicine 91 (6), 319-327, 2012 | 645 | 2012 |
| Adipokines and cytokines in non‐alcoholic fatty liver disease MH Jarrar, A Baranova, R Collantes, B Ranard, M Stepanova, C Bennett, ... Alimentary pharmacology & therapeutics 27 (5), 412-421, 2008 | 617 | 2008 |
| Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden Z Younossi, H Park, L Henry, A Adeyemi, M Stepanova Gastroenterology 150 (7), 1599-1608, 2016 | 470 | 2016 |
| Epidemiology of chronic liver diseases in the USA in the past three decades ZM Younossi, M Stepanova, Y Younossi, P Golabi, A Mishra, N Rafiq, ... Gut 69 (3), 564-568, 2020 | 437 | 2020 |
| Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population M Stepanova, ZM Younossi Clinical Gastroenterology and Hepatology 10 (6), 646-650, 2012 | 432 | 2012 |
| Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease N Hossain, A Afendy, M Stepanova, F Nader, M Srishord, N Rafiq, ... Clinical Gastroenterology and Hepatology 7 (11), 1224-1229. e2, 2009 | 400 | 2009 |
| Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States ZM Younossi, M Stepanova, J Ong, G Trimble, S AlQahtani, I Younossi, ... Clinical Gastroenterology and Hepatology 19 (3), 580-589. e5, 2021 | 379 | 2021 |
| Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study M Stepanova, N Rafiq, ZM Younossi Gut 59 (10), 1410-1415, 2010 | 369 | 2010 |
| A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH) ZM Younossi, M Jarrar, C Nugent, M Randhawa, M Afendy, M Stepanova, ... Obesity surgery 18, 1430-1437, 2008 | 346 | 2008 |
| Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD) M Stepanova, N Rafiq, H Makhlouf, R Agrawal, I Kaur, Z Younoszai, ... Digestive diseases and sciences 58, 3017-3023, 2013 | 328 | 2013 |
| In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009 M Stepanova, A Mishra, C Venkatesan, ZM Younossi Clinical gastroenterology and hepatology 10 (9), 1034-1041. e1, 2012 | 282 | 2012 |
| NASH in lean individuals R Younes, E Bugianesi Seminars in liver disease 39 (01), 086-095, 2019 | 245 | 2019 |
| Non‐alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population‐based study L Gerber, M Otgonsuren, A Mishra, C Escheik, A Birerdinc, M Stepanova, ... Alimentary pharmacology & therapeutics 36 (8), 772-781, 2012 | 245 | 2012 |
| Predictors of health‐related quality of life in patients with chronic liver disease A Afendy, JB Kallman, M Stepanova, Z Younoszai, RD Aquino, G Bianchi, ... Alimentary pharmacology & therapeutics 30 (5), 469-476, 2009 | 205 | 2009 |
| Caffeine is protective in patients with non‐alcoholic fatty liver disease A Birerdinc, M Stepanova, L Pawloski, ZM Younossi Alimentary pharmacology & therapeutics 35 (1), 76-82, 2012 | 195 | 2012 |
| Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir ZM Younossi, M Stepanova, N Afdhal, KV Kowdley, S Zeuzem, L Henry, ... Journal of hepatology 63 (2), 337-345, 2015 | 194 | 2015 |
Zobair YounossiThe Global NASH Council在 cldq.org 的电子邮件经过验证
